

## Neurizon Receives Additional R&D Tax Incentive Rebate

**11 December 2024 – Melbourne, Australia: Neurizon Therapeutics Limited** (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce that the Company has received an additional rebate of \$650,707 under the Federal Government’s Research and Development (R&D) Tax Incentive scheme in respect of eligible overseas expenditure incurred in the 2023/24 financial year, following submission of an Advance Overseas Finding Application to AusIndustry. This follows the initial R&D Tax Incentive Rebate received amounting to \$887,129 for eligible Australian or local expenditure incurred in the 2023/24 financial year, as announced on 9 October 2024.

**Dr. Michael Thurn, Managing Director and Chief Executive Officer of Neurizon, commented:** “We continue to appreciate the support that the Federal Government provides for our programs. This additional R&D Tax Incentive Rebate strengthens Neurizon’s cash position further and will be primarily applied toward preparations for the adaptive Phase 2/3 HEALEY ALS Platform Trial, GMP grade MPL manufacturing, preclinical models for other neurodegenerative diseases, regulatory filings and general working capital.”

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

**Dr. Michael Thurn**  
Managing Director and Chief Executive Officer  
Neurizon Therapeutics Limited  
[enquiries@neurizon.com](mailto:enquiries@neurizon.com)  
+61 (3) 9692 7222

**Catherine Strong**  
Sodali & Co  
[catherine.strong@sodali.com](mailto:catherine.strong@sodali.com)  
+61 (0)406 759 268

### About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients, while exploring NUZ-001’s potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

### Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>

